| Notice Filed with SOS |
01/25/2021 |
| Rule |
ProposedRuleAttach2021-00042.pdf |
| Additional Information |
AddInfoAttach2021-00042.pdf |
| Statutory Authority |
Sections 25-4-1004(1)(c)(I-IV), C.R.S. |
| Description of Subjects/Issues |
The proposed revisions include three changes to the current rule that will align the state’s newborn screening panel with the federal Recommended Uniform Screening Panel (RUSP). Division staff are requesting the addition of Glycogen Storage Disease Type II (Pompe Disease), Mucopolysaccharidosis Type 1 (MPS1), and X-linked Adrenoleukodystrophy (XALD) to the Colorado newborn screening panel. |
| Purpose/Objective of Rule |
The revisions include three changes to the current rule that will align the state’s newborn screening panel with the federal Recommended Uniform Screening Panel (RUSP). The revisions add Glycogen Storage Disease Type II (Pompe Disease), Mucopolysaccharidosis Type 1(MPS1), and X-linked Adrenoleukodystrophy (XALD) to the Colorado newborn screening panel. |
| Basis And Purpose |
BasisAndPurposeAttachment2021-00042.doc
|
| Regulatory analysis |
RegulatoryAnalysisAttachment2021-00042.doc
|
| Submitted in response to issues raised by COLS/OLLS? |
No
|
| Is this rule adopted in response to recent legislation? |
Yes
|
| Recent legislation bill number |
HB18-1006
|
| Hearing Date |
03/17/2021 |
| Hearing Time |
10:00 AM |
| Hearing Location |
Via Zoom: https://us02web.zoom.us/meeting/register/tZEvd-6ppjwpG9bXAsk3xQ9v0ewH0j6NxF6Q |
| Contact Name |
Emily Travanty |
| Contact Title |
Scientific Director |
| Contact Telephone |
303-692-3094 |
| Contact email |
emily.travanty@state.co.us |